The US FDA has granted Priority Review designation for tisagenlecleucel (Kymriah) for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for, or have relapsed after, ASCT.
A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.
Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.
A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine-induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient-derived vaccine-induced T cells.
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.
PD-L1 expression was more common among patients with the GCB subtype of diffuse large B-cell lymphoma, and PD-L1 positivity predicted shorter survival.
Treatment with carfilzomib for multiple myeloma was associated with increased incidence of cardiovascular adverse events, especially with higher doses.
BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.
Continuous treatment with lenalidomide/dexamethasone significantly improved survival in patients with transplant-ineligible newly diagnosed multiple myeloma.
Early disease progression for chronic lymphocytic leukemia was a robust prognostic factor for worse overall survival in patients treated with chemoimmunotherapy.